ImmunoGen Announces Conference Call to Discuss Its 2019 Operating Results
January 30 2020 - 4:01PM
Business Wire
ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that the Company will host a conference call at
8:00 a.m. ET on Friday, February 14, 2020 to discuss its 2019
operating results. Management will also provide a brief update on
the business.
Conference Call Information To access the live call by
phone, dial (877) 621-5803; the conference ID is 3989656. The call
may also be accessed through the Investors and Media section of the
Company’s website, www.immunogen.com. Following the webcast, a
replay of the call will be available at the same location.
ABOUT IMMUNOGEN ImmunoGen is developing the next
generation of antibody-drug conjugates to improve outcomes for
cancer patients. By generating targeted therapies with enhanced
anti-tumor activity and favorable tolerability profiles, we aim to
disrupt the progression of cancer and offer our patients more good
days. We call this our commitment to “target a better now.”
Learn more about who we are, what we do, and how we do it at
www.immunogen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200130005112/en/
INVESTOR RELATIONS AND MEDIA ImmunoGen Courtney O’Konek
781-895-0600 courtney.okonek@immunogen.com
OR
FTI Consulting Robert Stanislaro 212-850-5657
robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Sep 2023 to Sep 2024